Interestingly however, CTLA-4 blockade synergizes with BRAF inhibition in BRAF-wildtype colon carcinoma and fibrosarcoma mouse models (123); an effect attributed to the expansion of antigen specific T cells resulting from BRAFi-induced paradoxical activation of MAPK/ERK (123). This evidence concerns the gene BRAF and colon carcinoma.